Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 3/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16902802 | 0.97 | PLG (0.36) | PLGPLAUF2ST14F10 | |
| SCHEMBL16902805 | 0.94 | PLG (0.36) | PLGPLAUF2ST14F10 | |
| Hydrochloric Acid SCHEMBL16893917 | 0.93 | PLG (0.36) | PLGPLAUF2ST14F10 | |
| SCHEMBL16902798 | 0.91 | PLG (0.36) | PLGPLAUF2ST14F10 | |
| SCHEMBL13053833 | 0.91 | PLG (0.36) | PLGPLAUF2ST14F10 | |
| Hydrochloric Acid SCHEMBL16893822 | 0.90 | PLG (0.36) | PLGPLAUF2ST14F10 | |
| SCHEMBL16893905 | 0.90 | PLG (0.37) | PLGPLAUF2ST14F10 | |
| Hydrochloric Acid SCHEMBL16893611 | 0.90 | PLG (0.36) | PLGPLAUF2ST14F10 | |
| SCHEMBL29727820 | 0.89 | PLG (0.35) | PLGPLAUF2ST14F10 | |
| SCHEMBL29401478 | 0.88 | PLG (0.39) | PLGPLAUF2ST14F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | ARG1, ARGLU1, CGAS | PLG 2153/4885PLAU 1715/4885F2 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.